FAQ on Clene's Submission of Briefing Book to FDA for CNM-Au8(R) in ALS Treatment

What is Clene’s announcement about?

Clene announced plans to submit a briefing book to the FDA by July 13, 2024, for CNM-Au8(R), aiming to support its approval as a treatment for ALS through the accelerated approval process.

Why is the submission of the briefing book significant?

The submission is significant as it represents a critical step in obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8(R) as a treatment for ALS, potentially accelerating its approval.

What does the briefing book include?

The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023.

Who is involved in this announcement?

Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. are involved, focusing on enhancing mitochondrial health and protecting neuronal function to combat neurodegenerative diseases like ALS and MS.

When is the Type C interaction with the FDA scheduled?

The Type C interaction with the FDA is scheduled for the third quarter of 2024.

What is CNM-Au8?

CNM-Au8 is Clene’s primary therapeutic asset, a highly concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals aimed at treating neurodegenerative diseases.

How does CNM-Au8 work?

CNM-Au8 targets mitochondrial dysfunction and NAD+ decline, which are implicated in neuronal death in neurodegenerative diseases, though the exact mechanism is not detailed in the provided content.

Where can I find more information about Clene?

More information about Clene can be found in the company’s newsroom at https://ibn.fm/CLNN.

Who should I contact for more information?

For more information, you can contact IBN (InvestorBrandNetwork) at Editor@InvestorBrandNetwork.com or visit their website at https://www.InvestorBrandNetwork.com.